Tech Company Financing Transactions
Visterra Funding Round
Visterra, operating out of Waltham, raised $8.1 million in investment from Bill & Melinda Gates Foundation and Omega Funds.
Transaction Overview
Company Name
Announced On
12/2/2013
Transaction Type
Venture Equity
Amount
$8,100,000
Round
Series A
Proceeds Purpose
Proceeds will be used to further develop and validate Visterra's technology platform and advance its proprietary infectious disease product pipeline. The company's lead product candidate, VIS410, is a broad spectrum antibody for the prevention and treatment of both seasonal and pandemic influenza.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
275 2nd Ave.
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Visterra, Inc. is dedicated to the discovery and development of innovative products for the prevention, treatment and diagnosis of infectious diseases. The Company focuses on technologies that can interrogate how pathogens interact with human cells, a critical first step in the disease process.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brian Pereira
Chief Scientific Officer
Zachary Shriver
Vice President
Jean Bender
VP - Administration
Chris Kiefer
VP - Bus. Development
Greg Miller
VP - Finance
Todd Curtis
VP - R & D
Greg Babcock
Browse more venture capital transactions:
Prev: 12/2/2013: Biodesix venture capital transaction
Next: 12/2/2013: Xagenic venture capital transaction
Share this article
About Our VC Transactions Data
We record every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs